Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Smallpox Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Smallpox Overview | 8 | 1 |
| Pipeline Products for Smallpox Comparative Analysis | 9 | 1 |
| Smallpox Therapeutics under Development by Companies | 10 | 1 |
| Smallpox Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Smallpox Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Smallpox Products under Development by Companies | 14 | 1 |
| Smallpox Products under Investigation by Universities/Institutes | 15 | 1 |
| Smallpox Companies Involved in Therapeutics Development | 16 | 9 |
| Bavarian Nordic A/S | 16 | 1 |
| BioFactura, Inc. | 17 | 1 |
| CEL-SCI Corporation | 18 | 1 |
| Chimerix, Inc. | 19 | 1 |
| CJ HealthCare Corp. | 20 | 1 |
| EpiVax, Inc. | 21 | 1 |
| SIGA Technologies, Inc. | 22 | 1 |
| Takeda Pharmaceutical Company Limited | 23 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 24 | 1 |
| Smallpox Therapeutics Assessment | 25 | 10 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Combination Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 36 |
| (plague + small pox) vaccine Drug Profile | 35 | 1 |
| 24a Drug Profile | 36 | 1 |
| brincidofovir Drug Profile | 37 | 13 |
| CEL-1000 Drug Profile | 50 | 2 |
| CJ-40011 Drug Profile | 52 | 1 |
| imatinib mesylate Drug Profile | 53 | 1 |
| Monoclonal Antibodies for Infectious Disease Drug Profile | 54 | 1 |
| Monoclonal Antibody for Smallpox Drug Profile | 55 | 1 |
| nilotinib Drug Profile | 56 | 1 |
| PL-801 Drug Profile | 57 | 1 |
| SCV-305 Drug Profile | 58 | 1 |
| small pox vaccine Drug Profile | 59 | 1 |
| smallpox vaccine Drug Profile | 60 | 4 |
| smallpox vaccine Drug Profile | 64 | 1 |
| tecovirimat Drug Profile | 65 | 5 |
| VIR-002 Drug Profile | 70 | 1 |
| Smallpox Dormant Projects | 71 | 2 |
| Smallpox Discontinued Products | 73 | 1 |
| Smallpox Product Development Milestones | 74 | 9 |
| Featured News &Press Releases | 74 | 1 |
| Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government | 74 | 1 |
| Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA s Tecovirimat Antiviral | 74 | 1 |
| Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox | 74 | 1 |
| Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene | 75 | 1 |
| Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox | 75 | 1 |
| Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox | 76 | 1 |
| Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million | 76 | 1 |
| May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine | 77 | 1 |
| Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery | 78 | 1 |
| Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess ... | 78 | 1 |
| Dec 23, 2014: Chimerix Provides Recap of 2014 Events | 79 | 1 |
| Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine | 80 | 1 |
| Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine | 80 | 1 |
| Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox | 81 | 1 |
| Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine | 81 | 2 |
| Appendix | 83 | 2 |
| Methodology | 83 | 1 |
| Coverage | 83 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 83 | 1 |
| Disclaimer | 84 | 1 |